abstract: BACKGROUND: Mortality in early stage, resectable @entity2 is sufficiently high to warrant consideration of post-surgical treatment. Novel markers to stratify resectable @entity2 @entity1 may help with the selection of treatment to improve outcome. METHODS: Primary @entity5 tissue from 485 @entity1 , surgically treated for stage I-II @entity2220 , was analysed for the RNA expression of 31 cell cycle progression (CCP) genes by quantitative polymerase chain reaction (PCR). The expression average, the CCP score, was combined with pathological stage into a prognostic score (PS). Cox proportional hazards regression assessed prediction of 5-year @entity2 mortality above clinical variables. The PS threshold was tested for risk discrimination by the Mantel-Cox log-rank test. RESULTS: The CCP score added significant information above clinical markers (all @entity1 , P=0.0029; stage I @entity1 , P=0.013). The prognostic score was a superior predictor of outcome compared to pathological stage alone (PS, P=0.00084; stage, P=0.24). Five-year @entity2 mortality was significantly different between the low-risk (90%, 95% confidence interval (CI) 81-95%), and high-risk groups (65%, 95% CI 57-72%), P=4.2*10(-6)). CONCLUSIONS: The CCP score is an independent prognostic marker in early stage @entity2220 . The prognostic score provides superior risk estimates than stage alone. The threefold higher risk in the high-risk group defines a subset of @entity1 that should consider therapeutic choices to improve outcome.

title: Stratification of resectable XXXX by molecular and pathological risk estimators.

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

answer: @entity2220 :: (MESH:C538231,Disease) :: ['lung adenocarcinoma']


abstract: BACKGROUND: The aim of this study was to analyzed the characteristics and treatment of @entity11253 in the elder @entity1 with @entity11253 in central China. MATERIAL AND METHODS: We retrospectively analyzed the characteristics and treatment of @entity11253 in the @entity1 over the age of 60 to analyze the trends and clinical characteristics of maxillofacial @entity130 in elder @entity1 from the First Affiliated Hospital of Zhengzhou University (from 2010 to 2013) in central China and to present recommendations on prevention and management. RESULTS: Of the 932 @entity1 with @entity11253 , 126 aged over 60 years old accounting for 13.52% of all the @entity1 (male:female, 1.74:1; mean age, 67.08 years old). Approximately 52% of the @entity1 were injured by falls. The most frequently observed type of injuries was soft tissue injuries (100%), followed by @entity174 (83.05%). Of the @entity1 with soft tissue injuries, the abrasions accounted the most, followed by lacerations. The numbers of @entity1 of midface @entity174 (60 @entity1 ) were almost similar to the number of lower face @entity174 (66 @entity1 ). Eighty two @entity1 (65.08%%) demonstrated associated injuries, of which @entity542 were the most prevalent. One hundred and four @entity1 (82.54%) had other systemic medical conditions, with @entity65 the most and followed by @entity85 . Furthermore, the study indicated a relationship between maxillofacial @entity174 and @entity85 . Only 13 @entity1 (10.32%) sustained local infections, of whom had other medical conditions. Most of the @entity8494 (85.71%) in older @entity1 were operated including debridement, fixing loose teeth, reduction, intermaxillary fixation and open reduction and internal fixation (ORIF). CONCLUSIONS: Our analysis of the characteristics of @entity11253 in the elder patents may help to promote clinical research to develop more effective treatment and possibly prevent such injuries.

title: Analysis of 126 hospitalized elder maxillofacial XXXX victims in central China.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity11253 :: ('MESH:D008446', 'Disease') :: ['maxillofacial injuries']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture', 'facial fractures']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['craniocerebral injuries']

entities_list: @entity8494 :: ('MESH:D005151', 'Disease') :: ['facial injuries']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['metabolic diseases and musculoskeletal conditions', 'musculoskeletal conditions']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']

answer: @entity130 :: (MESH:D014947,Disease) :: ['trauma']


abstract: OBJECTIVE: Although imaging surveillance is mandatory for all @entity1 after @entity439 repair (EVAR), many @entity1 are not compliant with follow-up. We sought to determine predictors of compliance with EVAR surveillance and to examine how compliance with current surveillance protocols correlates with survival. METHODS: We analyzed 188 @entity1 who underwent EVAR at our institution for @entity1028 (AAAs) between 2001 and 2011. The primary end point was compliance with post-EVAR surveillance recommendations. Univariate analysis included @entity1 demographics and socioeconomic information, AAA characteristics, EVAR hospital course variables, late complications and secondary interventions, length of follow-up, smoking status, family history of AAA, driving distances, primary care providers, and medical comorbidities. Mortality was determined by the Social Security Death Index. Multinomial logistic regressions were fit to identify independent predictors of compliance. Survival plots were generated with the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate Cox regression analysis was used to determine effect of compliance on survival after adjusting for confounders. RESULTS: Of 188 @entity1 , 89 (47.3%) were 100% compliant with follow-up visits and imaging, 21 (11.1%) were moderately compliant by missing appointments, and 78 (41.4%) were lost to follow-up completely. Overall median age was 74  years, and 81.9% of @entity1 were male. Late complications occurred in 77 @entity1 (40.9%), secondary interventions were performed in 32 @entity1 (17%), and 5-year mortality was 21.2%. Mean follow-up interval was >40  months for 100% compliant and moderately compliant @entity1 and  <20  months for those lost to follow-up (P  < .0001). In adjusted analysis, late complications (odds ratio [OR], 2.71; 95% confidence interval [CI], 1.32-5.55; P  = .007), @entity6100 (OR, 2.43; 95% CI, 1.12-5.27; P  = .024), and family history of AAA (OR, 2.67; 95% CI, 1.06-6.75; P  = .037) were associated with 100% compliance, whereas shorter driving distances (P  = .051) and shorter hospital stay (P  = .056) approached significance. Transient @entity63 attack or @entity64 (OR, 3.59; 95% CI, 1.18-10.91; P  = .024) was the only variable independently associated with moderate compliance. Compared with @entity1 lost to follow-up, 100% compliant @entity1 had worse survival (log-rank test, P  = .033), whereas moderately compliant @entity1 ' survival was not significantly different (log-rank test, P  = .149). In adjusted Cox regression analysis, 100% compliant @entity1 had decreased survival duration (rate ratio, 2.67; 95% CI, 1.18-6.06; P  = .018) compared with those lost to follow-up. CONCLUSIONS: Follow-up surveillance is incomplete for more than half of @entity1 who undergo EVAR at our institution, and @entity1 compliance can be predicted by covariates mentioned before. Compliance with current surveillance regimens does not confer a survival benefit. Further research individualizing surveillance protocols based on risk level of late complications and noncompliance and prospective studies examining resulting survival benefits of compliance are warranted.

title: Predictors of compliance with surveillance after XXXX repair and comparative survival outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity6100 :: ('OMIM:300082', 'Disease') :: ['absence of social work consultation']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['endovascular aneurysm']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['infrarenal abdominal aortic aneurysms']

answer: @entity439 :: (MESH:D000783,Disease) :: ['endovascular aneurysm']


abstract: BACKGROUND: Pareidolia, which is a particular type of complex @entity227 , has been reported to be a phenomenon analogous to @entity1833 in @entity1 with @entity303 with @entity1832 . However, whether pareidolia is observed in @entity191 ( @entity191 ) or whether there are common underlying mechanisms of these two types of @entity227 remains to be elucidated. METHODS: A test to evoke pareidolia, the Pareidolia test, was administered to 53 @entity1 with @entity191 without @entity303 and 24 healthy controls. The regional cerebral metabolic rate of @entity413 was measured using @entity419 positron emission tomography in the @entity191 @entity1 . RESULTS: @entity191 @entity1 without @entity303 produced a greater number of @entity10582 compared with the controls. Pareidolia was observed in all of the @entity1 having @entity1833 as well as a subset of those without @entity1833 . The number of @entity10582 was correlated with hypometabolism in the bilateral temporal, parietal and occipital cortices. The index of @entity1833 was correlated with hypometabolism in the left parietal cortex. A region associated with both pareidolia and @entity1833 was found in the left parietal lobe. CONCLUSIONS: Our study suggests that @entity191 @entity1 without @entity303 experience pareidolia more frequently than healthy controls and that posterior @entity409 could be a common neural mechanism of pareidolia and @entity1833 . Pareidolia could represent subclinical @entity1833 or a predisposition to @entity1833 in @entity1832 .

title: Pareidolia in XXXX without @entity303 : A positron emission tomography study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual misperceptions', 'visual illusion']

entities_list: @entity419 :: ('MESH:D019788', 'Chemical') :: ['18F-fluorodeoxyglucose']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['cortical dysfunction']

entities_list: @entity10582 :: ('MESH:D007088', 'Disease') :: ['pareidolic illusions']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ['PD', "Parkinson's disease"]

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['visual hallucinations', 'hallucinations']

entities_list: @entity1832 :: ('MESH:D020961', 'Disease') :: ['Lewy body disease', 'Lewy bodies']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: BACKGROUND: Pareidolia, which is a particular type of complex @entity227 , has been reported to be a phenomenon analogous to @entity1833 in @entity1 with @entity303 with @entity1832 . However, whether pareidolia is observed in @entity191 ( @entity191 ) or whether there are common underlying mechanisms of these two types of @entity227 remains to be elucidated. METHODS: A test to evoke pareidolia, the Pareidolia test, was administered to 53 @entity1 with @entity191 without @entity303 and 24 healthy controls. The regional cerebral metabolic rate of @entity413 was measured using @entity419 positron emission tomography in the @entity191 @entity1 . RESULTS: @entity191 @entity1 without @entity303 produced a greater number of @entity10582 compared with the controls. Pareidolia was observed in all of the @entity1 having @entity1833 as well as a subset of those without @entity1833 . The number of @entity10582 was correlated with hypometabolism in the bilateral temporal, parietal and occipital cortices. The index of @entity1833 was correlated with hypometabolism in the left parietal cortex. A region associated with both pareidolia and @entity1833 was found in the left parietal lobe. CONCLUSIONS: Our study suggests that @entity191 @entity1 without @entity303 experience pareidolia more frequently than healthy controls and that posterior @entity409 could be a common neural mechanism of pareidolia and @entity1833 . Pareidolia could represent subclinical @entity1833 or a predisposition to @entity1833 in @entity1832 .

title: Pareidolia in @entity191 without XXXX : A positron emission tomography study.

answer: @entity303 :: (MESH:D003704,Disease) :: ['dementia']


abstract: BACKGROUND: The purpose of this study was to investigate the relative contributions of two proposed mechanisms, strength imbalance and @entity121 , to @entity85 in a @entity35 model of @entity5300 ( @entity5300 ). METHODS: Thirty-two @entity35 pups were divided into four groups on the basis of surgical interventions to induce a strength imbalance, impaired growth, both a strength imbalance and impaired growth (a combined mechanism), and a sham condition in the left forelimb. Maximum passive external shoulder rotation angle (ERmax) was measured bilaterally at four and eight weeks postoperatively. After the @entity35 were killed at eight weeks, the glenohumeral geometry (on microcomputed tomography) and shoulder muscle architecture properties were measured bilaterally. RESULTS: Bilateral muscle mass and optimal length differences were greatest in the impaired growth and combined mechanism groups, which also exhibited >15   lower ERmax (p < 0.05; four weeks postoperatively), 14   to 18   more @entity810 (p < 0.10), and 0.76 to 0.94 mm more inferior humeral head translation (p < 0.10) on the affected side. Across all four groups, optimal muscle length was significantly correlated with at least one @entity85 measure for six of fourteen muscle compartments crossing the shoulder on the affected side (p < 0.05). In the strength imbalance group, the glenoid was 5   more inclined and the humeral head was translated 7.5% more posteriorly on the affected side (p < 0.05). CONCLUSIONS: @entity121 and @entity85 were most pronounced in the impaired growth and combined mechanism groups, which underwent neurectomy. Strength imbalance was associated with @entity85 to a lesser extent. CLINICAL RELEVANCE: Treatments to alleviate @entity85 should address mechanical effects of both strength imbalance and @entity121 , with an emphasis on developing new treatments to promote growth in muscles affected by @entity5300 .

title: Biomechanical Basis of Shoulder Osseous Deformity and Contracture in a @entity35 Model of XXXX .

entities_list: @entity5300 :: ('MESH:D020516', 'Disease') :: ['BPBP', 'brachial plexus birth palsy']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['glenoid declination']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rat', 'rats']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['osseous deformity', 'osseous and postural deformity', 'shoulder deformity']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['impaired longitudinal muscle growth', 'Impaired longitudinal muscle growth']

answer: @entity5300 :: (MESH:D020516,Disease) :: ['Brachial Plexus Birth Palsy']


abstract: BACKGROUND: The purpose of this study was to investigate the relative contributions of two proposed mechanisms, strength imbalance and @entity121 , to @entity85 in a @entity35 model of @entity5300 ( @entity5300 ). METHODS: Thirty-two @entity35 pups were divided into four groups on the basis of surgical interventions to induce a strength imbalance, impaired growth, both a strength imbalance and impaired growth (a combined mechanism), and a sham condition in the left forelimb. Maximum passive external shoulder rotation angle (ERmax) was measured bilaterally at four and eight weeks postoperatively. After the @entity35 were killed at eight weeks, the glenohumeral geometry (on microcomputed tomography) and shoulder muscle architecture properties were measured bilaterally. RESULTS: Bilateral muscle mass and optimal length differences were greatest in the impaired growth and combined mechanism groups, which also exhibited >15   lower ERmax (p < 0.05; four weeks postoperatively), 14   to 18   more @entity810 (p < 0.10), and 0.76 to 0.94 mm more inferior humeral head translation (p < 0.10) on the affected side. Across all four groups, optimal muscle length was significantly correlated with at least one @entity85 measure for six of fourteen muscle compartments crossing the shoulder on the affected side (p < 0.05). In the strength imbalance group, the glenoid was 5   more inclined and the humeral head was translated 7.5% more posteriorly on the affected side (p < 0.05). CONCLUSIONS: @entity121 and @entity85 were most pronounced in the impaired growth and combined mechanism groups, which underwent neurectomy. Strength imbalance was associated with @entity85 to a lesser extent. CLINICAL RELEVANCE: Treatments to alleviate @entity85 should address mechanical effects of both strength imbalance and @entity121 , with an emphasis on developing new treatments to promote growth in muscles affected by @entity5300 .

title: Biomechanical Basis of Shoulder Osseous Deformity and Contracture in a XXXX Model of @entity5300 .

answer: @entity35 :: (10116,Species) :: ['Rat']


abstract: The constitutively expressed @entity1457 protein 70 kDa ( @entity9487 ) is a major chaperone protein responsible for maintaining @entity5085 , yet how its structure translates into functional decisions regarding client fate is still unclear. We previously showed that @entity9487 preserved aberrant Tau, but it remained unknown if selective inhibition of the activity of this @entity2285 isoform could facilitate Tau clearance. Using single point mutations in the @entity4334 binding domain, we assessed the effect of several mutations on the functions of @entity1 @entity9487 . Biochemical characterization revealed that one mutation abolished both @entity9487 ATPase and refolding activities. This variant resembled the @entity857 -bound conformer at all times yet remained able to interact with cofactors, @entity2036 , and substrates appropriately, resembling a dominant negative @entity9487 (DN- @entity9487 ). We then assessed the effects of this DN- @entity9487 on its client Tau. DN- @entity9487 potently facilitated Tau clearance via the proteasome in cells and brain tissue, in contrast to wild type @entity9487 that stabilized Tau. Thus, DN- @entity9487 mimics the action of small molecule pan @entity2285 inhibitors with regard to Tau metabolism. This shift in @entity9487 function by a single point mutation was the result of a change in the chaperome associated with @entity9487 such that DN- @entity9487 associated more with @entity4041 and DnaJ proteins, whereas wild type @entity9487 was more associated with other @entity2285 isoforms. Thus, isoform-selective targeting of @entity9487 could be a viable therapeutic strategy for @entity13859 and possibly lead to new insights in chaperone complex biology.

title: Isoform-selective Genetic Inhibition of Constitutive Cytosolic XXXX Activity Promotes Client Tau Degradation Using an Altered Co-chaperone Complement.

entities_list: @entity5085 :: ('MESH:D057165', 'Disease') :: ['proteostasis']

entities_list: @entity1457 :: ('MESH:D012769', 'Disease') :: ['heat shock']

entities_list: @entity2036 :: ('MESH:D009711', 'Chemical') :: ['nucleotides']

entities_list: @entity13859 :: ('MESH:D024801', 'Disease') :: ['tauopathies']

answer: @entity2285 :: (3308,Gene) :: ['Hsp70']


abstract: The electrophysiologic effects and safety of @entity3988 administered either intravenously or orally were studied in 14 @entity1 with @entity3153 during orthodromic reentrant @entity591 and @entity955 ( @entity955 ). Anterograde and retrograde effective refractory periods of the accessory pathway did not change significantly from baseline during either i.v. or oral administration. Administration by either route prevented induction of sustained reentrant @entity591 in 8 @entity1 . In 6 @entity1 , the reentrant @entity591 was either nonsustained (2 @entity1 ) or sustained at much slower rates than the baseline rates (mean +/- standard deviation, baseline, 290 +/- 41 ms; i.v., 355 +/- 40 ms [p less than 0.001]; and oral, 377 +/- 33 ms [p less than 0.001]). In these @entity1 anterograde atrioventricular conduction was prolonged significantly from the mean baseline value of 163 +/- 36 ms to 212 +/- 35 ms with i.v. administration (p less than 0.005) and 225 +/- 33 ms with oral administration (p less than 0.005). Retrograde conduction via the accessory pathway did not change significantly after administration of @entity3988 . The shortest preexcited RR intervals during @entity955 were significantly reduced during i.v. but not during oral administration: control, 327 +/- 47 ms; i.v., 270 +/- 28 ms (p less than 0.001); and oral, 323 +/- 44 ms (difference not significant). In 5 @entity1 @entity955 was sustained for a mean of 20 minutes after i.v. and for 12 minutes after oral administration (p less than 0.20), compared with a baseline mean value of 0.83 minute.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of intravenous and oral @entity3988 for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3988 :: ('MESH:D004110', 'Chemical') :: ['diltiazem']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF']

entities_list: @entity3153 :: ('MESH:D014927', 'Disease') :: ['Wolff-Parkinson-White syndrome']

answer: @entity3153 :: (MESH:D014927,Disease) :: ['Wolff-Parkinson-White syndrome']


abstract: The electrophysiologic effects and safety of @entity3988 administered either intravenously or orally were studied in 14 @entity1 with @entity3153 during orthodromic reentrant @entity591 and @entity955 ( @entity955 ). Anterograde and retrograde effective refractory periods of the accessory pathway did not change significantly from baseline during either i.v. or oral administration. Administration by either route prevented induction of sustained reentrant @entity591 in 8 @entity1 . In 6 @entity1 , the reentrant @entity591 was either nonsustained (2 @entity1 ) or sustained at much slower rates than the baseline rates (mean +/- standard deviation, baseline, 290 +/- 41 ms; i.v., 355 +/- 40 ms [p less than 0.001]; and oral, 377 +/- 33 ms [p less than 0.001]). In these @entity1 anterograde atrioventricular conduction was prolonged significantly from the mean baseline value of 163 +/- 36 ms to 212 +/- 35 ms with i.v. administration (p less than 0.005) and 225 +/- 33 ms with oral administration (p less than 0.005). Retrograde conduction via the accessory pathway did not change significantly after administration of @entity3988 . The shortest preexcited RR intervals during @entity955 were significantly reduced during i.v. but not during oral administration: control, 327 +/- 47 ms; i.v., 270 +/- 28 ms (p less than 0.001); and oral, 323 +/- 44 ms (difference not significant). In 5 @entity1 @entity955 was sustained for a mean of 20 minutes after i.v. and for 12 minutes after oral administration (p less than 0.20), compared with a baseline mean value of 0.83 minute.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of intravenous and oral XXXX for @entity3153 .

answer: @entity3988 :: (MESH:D004110,Chemical) :: ['diltiazem']


abstract: OBJECTIVE: The current study aimed to analyze the short-term and long-term curative effects of @entity842 (NO) inhalation combined with high-frequency oscillatory ventilation (HFOV) on neonatal severe @entity519 . MATERIALS AND METHODS: A total of 98 neonates meeting the inclusion criteria were retrospectively analyzed. The control group comprised of 48 neonates and the NO inhalation group consisted of 50 neonates. In the control group, conventional mechanical ventilation was replaced by HFOV. In the experimental group, NO inhalation combined with HFOV was performed. The @entity204 rates within 28 days, mechanical ventilation and @entity26 therapy time, and complications in both groups were observed. The survivors in both groups were followed up for 18 months for neural development evaluation. RESULTS: The treatment group showed a significantly lower @entity204 rate and noticeably shorter mechanical ventilation and @entity26 therapy time than the control group (8% vs. 22.9% with t = 4.20 andp < 0.05; 5.84    3.36 days vs. 8.05    5.48 days with t = 2.42 and p < 0.05; and 8.02    4.31 days vs. 12.45    5.14 days with t = 4.63 and p < 0.001). They did not show significant differences with regards to the complications and the incidences of @entity306 , hearing and @entity227 , and severe @entity16 (p > 0.05). CONCLUSION: NO inhalation combined with HFOV significantly decreases the @entity204 rate of neonates with severe @entity519 and reduces their mechanical ventilation and @entity26 therapy time. It does not increase early adverse effects or affect long-term neurodevelopment.

title: Effect of @entity842 inhalation combined with high-frequency oscillatory ventilation on the prognosis of neonatal severe XXXX .

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairments']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['nervous damage']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxemia']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity306 :: ('MESH:D002547', 'Disease') :: ['cerebral palsy']

answer: @entity519 :: (MESH:D000860,Disease) :: ['hypoxemia']


abstract: OBJECTIVE: The current study aimed to analyze the short-term and long-term curative effects of @entity842 (NO) inhalation combined with high-frequency oscillatory ventilation (HFOV) on neonatal severe @entity519 . MATERIALS AND METHODS: A total of 98 neonates meeting the inclusion criteria were retrospectively analyzed. The control group comprised of 48 neonates and the NO inhalation group consisted of 50 neonates. In the control group, conventional mechanical ventilation was replaced by HFOV. In the experimental group, NO inhalation combined with HFOV was performed. The @entity204 rates within 28 days, mechanical ventilation and @entity26 therapy time, and complications in both groups were observed. The survivors in both groups were followed up for 18 months for neural development evaluation. RESULTS: The treatment group showed a significantly lower @entity204 rate and noticeably shorter mechanical ventilation and @entity26 therapy time than the control group (8% vs. 22.9% with t = 4.20 andp < 0.05; 5.84    3.36 days vs. 8.05    5.48 days with t = 2.42 and p < 0.05; and 8.02    4.31 days vs. 12.45    5.14 days with t = 4.63 and p < 0.001). They did not show significant differences with regards to the complications and the incidences of @entity306 , hearing and @entity227 , and severe @entity16 (p > 0.05). CONCLUSION: NO inhalation combined with HFOV significantly decreases the @entity204 rate of neonates with severe @entity519 and reduces their mechanical ventilation and @entity26 therapy time. It does not increase early adverse effects or affect long-term neurodevelopment.

title: Effect of XXXX inhalation combined with high-frequency oscillatory ventilation on the prognosis of neonatal severe @entity519 .

answer: @entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']


abstract: The incidence and severity of abnormalities of the coronary arteries were evaluated in 35 necropsy @entity1 with @entity1146 and an intact @entity67 . Right ventricular to coronary artery fistulous connections were found in more than 60% of the cases. All @entity1 with fistulous connections had histologic abnormalities of the coronary arteries. In 50% the lesions were mild, with medial and intimal thickening producing up to moderate @entity850 . In 50% there was loss of normal arterial wall structure and severe @entity543 or obliteration of the arterial lumen. The coronary arterial fistulas and histologic abnormalities were prevalent in those with underdevelopment of the tricuspid valve and right ventricular cavity but were not found in @entity1 with a normal or dilated tricuspid valve anulus. The @entity453 were found in more than 80% of @entity1 with a tricuspid valve/mitral valve ratio less than 1. A single coronary artery occurred in 6 @entity1 (17%) of this series. In 80% of those with 1 coronary artery arising from the other, the aberrantly arising coronary artery crossed anteriorly to the pulmonary artery and could be at risk in surgical attempts to reconstruct the right ventricular outflow. Aortography is recommended if the coronary arteries are not clearly delineated on @entity67 .

title: @entity453 in @entity1146 with intact XXXX .

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['luminal stenosis']

entities_list: @entity1146 :: ('MESH:D018633', 'Disease') :: ['pulmonary atresia']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary arterial abnormalities']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular cineangiocardiography', 'ventricular septum']

entities_list: @entity543 :: ('MESH:D016893', 'Disease') :: ['narrowing']

answer: @entity67 :: (MESH:D018754,Disease) :: ['ventricular septum']


abstract: The incidence and severity of abnormalities of the coronary arteries were evaluated in 35 necropsy @entity1 with @entity1146 and an intact @entity67 . Right ventricular to coronary artery fistulous connections were found in more than 60% of the cases. All @entity1 with fistulous connections had histologic abnormalities of the coronary arteries. In 50% the lesions were mild, with medial and intimal thickening producing up to moderate @entity850 . In 50% there was loss of normal arterial wall structure and severe @entity543 or obliteration of the arterial lumen. The coronary arterial fistulas and histologic abnormalities were prevalent in those with underdevelopment of the tricuspid valve and right ventricular cavity but were not found in @entity1 with a normal or dilated tricuspid valve anulus. The @entity453 were found in more than 80% of @entity1 with a tricuspid valve/mitral valve ratio less than 1. A single coronary artery occurred in 6 @entity1 (17%) of this series. In 80% of those with 1 coronary artery arising from the other, the aberrantly arising coronary artery crossed anteriorly to the pulmonary artery and could be at risk in surgical attempts to reconstruct the right ventricular outflow. Aortography is recommended if the coronary arteries are not clearly delineated on @entity67 .

title: @entity453 in XXXX with intact @entity67 .

answer: @entity1146 :: (MESH:D018633,Disease) :: ['pulmonary atresia']


abstract: The incidence and severity of abnormalities of the coronary arteries were evaluated in 35 necropsy @entity1 with @entity1146 and an intact @entity67 . Right ventricular to coronary artery fistulous connections were found in more than 60% of the cases. All @entity1 with fistulous connections had histologic abnormalities of the coronary arteries. In 50% the lesions were mild, with medial and intimal thickening producing up to moderate @entity850 . In 50% there was loss of normal arterial wall structure and severe @entity543 or obliteration of the arterial lumen. The coronary arterial fistulas and histologic abnormalities were prevalent in those with underdevelopment of the tricuspid valve and right ventricular cavity but were not found in @entity1 with a normal or dilated tricuspid valve anulus. The @entity453 were found in more than 80% of @entity1 with a tricuspid valve/mitral valve ratio less than 1. A single coronary artery occurred in 6 @entity1 (17%) of this series. In 80% of those with 1 coronary artery arising from the other, the aberrantly arising coronary artery crossed anteriorly to the pulmonary artery and could be at risk in surgical attempts to reconstruct the right ventricular outflow. Aortography is recommended if the coronary arteries are not clearly delineated on @entity67 .

title: XXXX in @entity1146 with intact @entity67 .

answer: @entity453 :: (MESH:D003324,Disease) :: ['Coronary arterial abnormalities']


abstract: OBJECTIVE: To demonstrate the utility of electromyography (EMG) in the evaluation and management of treatment-resistant @entity7364 . METHOD: We report a case of @entity7364 in which EMG was used to identify and treat isolated cricothyroid (CT) @entity3519 . RESULTS: The @entity1 , a healthy 43-year-old @entity1 , presented with 9  months of progressive hoarseness. Her symptoms were present across vocal tasks but were particularly bothersome while dictating. On presentation, her voice was rated grade 3, roughness 3, breathiness 1, asthenia 0, and strain 3 (G3R3B1A0S3). Videostroboscopy was remarkable for @entity6392 . Voice therapy was not beneficial despite appropriate effort. Microdirect laryngoscopy revealed no evidence of structural pathology. The @entity1 was referred for EMG because of her normal examination and failure to improve with therapy. The CT muscle demonstrated an increased latency of 750  ms in all vocal tasks. One month after CT injection with 3 units of botulinum toxin (BTX), her voice was improved. Perceptual voice evaluation was rated G1R1B0A0S1. Voice Handicap Index improved from 87 to  35. CONCLUSIONS: In the absence of structural pathology, EMG can be a useful adjunct in the diagnosis of @entity7364 that persists despite adequate trials of voice therapy. To our knowledge, this is the only report of @entity3519 due to isolated @entity409 successfully treated with BTX.

title: XXXX Due to Isolated @entity3519 .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['CT dysfunction']

entities_list: @entity7364 :: ('MESH:D055154', 'Disease') :: ['dysphonia', 'refractory dysphonia']

entities_list: @entity6392 :: ('MESH:D000308', 'Disease') :: ['hyperfunction']

entities_list: @entity3519 :: ('MESH:D004421', 'Disease') :: ['laryngeal dystonia', 'dystonia']

answer: @entity7364 :: (MESH:D055154,Disease) :: ['Refractory Dysphonia']


abstract: OBJECTIVE: To demonstrate the utility of electromyography (EMG) in the evaluation and management of treatment-resistant @entity7364 . METHOD: We report a case of @entity7364 in which EMG was used to identify and treat isolated cricothyroid (CT) @entity3519 . RESULTS: The @entity1 , a healthy 43-year-old @entity1 , presented with 9  months of progressive hoarseness. Her symptoms were present across vocal tasks but were particularly bothersome while dictating. On presentation, her voice was rated grade 3, roughness 3, breathiness 1, asthenia 0, and strain 3 (G3R3B1A0S3). Videostroboscopy was remarkable for @entity6392 . Voice therapy was not beneficial despite appropriate effort. Microdirect laryngoscopy revealed no evidence of structural pathology. The @entity1 was referred for EMG because of her normal examination and failure to improve with therapy. The CT muscle demonstrated an increased latency of 750  ms in all vocal tasks. One month after CT injection with 3 units of botulinum toxin (BTX), her voice was improved. Perceptual voice evaluation was rated G1R1B0A0S1. Voice Handicap Index improved from 87 to  35. CONCLUSIONS: In the absence of structural pathology, EMG can be a useful adjunct in the diagnosis of @entity7364 that persists despite adequate trials of voice therapy. To our knowledge, this is the only report of @entity3519 due to isolated @entity409 successfully treated with BTX.

title: @entity7364 Due to Isolated XXXX .

answer: @entity3519 :: (MESH:D004421,Disease) :: ['Cricothyroid Muscle Dystonia']


abstract: Five @entity95 were allotted to each of six treatments on a matched-individual basis. Treatments were none, sham, total adrenalectomy with adrenocorticoid replacement, intravenous @entity2997 (15 mg X kg-1 X day-1), adrenalectomy + @entity2997 , and adrenal medullectomy. The conscious @entity95 were bled 20 ml/kg over 5 min. @entity1510 (6 mg/kg) was injected intravenously. The responses of arterial pressure and of plasma @entity1425 (E) and @entity1063 (NE) concentrations were measured. Factorial analysis was used to calculate the effects of sympathetic noradrenergic nerves (SYM) and the adrenal medulla (ADR) on the responses. In combination, SYM + ADR fully accounted for the pressor response observed in normal and sham-treated @entity95 . SYM and ADR each made independent and approximately equal contributions to the response, but the SYM X ADR interaction was strongly antagonistic. The responses of plasma E and NE were fully accounted for by the adrenal glands and sympathetic nerves, respectively. The pressor responses after total adrenalectomy and adrenal medullectomy were similar. Thus @entity548 -stimulated adrenal corticosteroid release was not essential to @entity1510 's action, and adrenal enkephalins were not responsible for @entity1510 's action on sympathetic pathways.

title: Sympathoadrenal mechanisms in cardiovascular responses to XXXX after @entity548 .

entities_list: @entity2997 :: ('MESH:D006145', 'Chemical') :: ['guanethidine']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['Naloxone', 'naloxone']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity1510 :: (MESH:D009270,Chemical) :: ['naloxone']


abstract: Five @entity95 were allotted to each of six treatments on a matched-individual basis. Treatments were none, sham, total adrenalectomy with adrenocorticoid replacement, intravenous @entity2997 (15 mg X kg-1 X day-1), adrenalectomy + @entity2997 , and adrenal medullectomy. The conscious @entity95 were bled 20 ml/kg over 5 min. @entity1510 (6 mg/kg) was injected intravenously. The responses of arterial pressure and of plasma @entity1425 (E) and @entity1063 (NE) concentrations were measured. Factorial analysis was used to calculate the effects of sympathetic noradrenergic nerves (SYM) and the adrenal medulla (ADR) on the responses. In combination, SYM + ADR fully accounted for the pressor response observed in normal and sham-treated @entity95 . SYM and ADR each made independent and approximately equal contributions to the response, but the SYM X ADR interaction was strongly antagonistic. The responses of plasma E and NE were fully accounted for by the adrenal glands and sympathetic nerves, respectively. The pressor responses after total adrenalectomy and adrenal medullectomy were similar. Thus @entity548 -stimulated adrenal corticosteroid release was not essential to @entity1510 's action, and adrenal enkephalins were not responsible for @entity1510 's action on sympathetic pathways.

title: Sympathoadrenal mechanisms in cardiovascular responses to @entity1510 after XXXX .

answer: @entity548 :: (MESH:D006470,Disease) :: ['hemorrhage']


abstract: The role of sympathetic efferent innervation of the carotid sinus on the regulation of baroreceptor sensitivity was examined in thiopental- @entity1372 anesthetized @entity235 (5 mg X kg-1 X h-1 infusion). Baroreflex sensitivity was defined as the slope of renal sympathetic efferent nerve activity vs. carotid sinus pressure in an isolated, perfused carotid sinus. Slopes were obtained before and after sinus sympathectomy performed by section of the cervical sympathetic trunk. There was no significant differences between baroreflex decreases in renal sympathetic activity due to increases in carotid sinus pressure before and after sympathectomy, but the responses to decreases in carotid sinus pressure after sympathectomy were significantly greater than control. Base-line level of renal sympathetic activity, obtained at a constant perfusion pressure of 115 mmHg, abruptly increased by 11% in response to sinus sympathectomy. The response of baroreceptors to sympathomimetic stimulation was examined by recording carotid baroreceptor afferent nerve activity during ramp changes in carotid sinus pressure after addition of @entity1425 (10(-8) to 10(-6) M) to the perfusate of the sympathetically denervated sinus. The slopes of the sinus nerve activity vs. carotid sinus pressure were used as direct indexes of baroreceptor sensitivity. Lower levels of @entity1425 (10(-8), 10(-7) M) increased the sensitivity of the baroreceptors and reduced @entity8 back toward presympathectomy levels. A higher dose of @entity1425 (10(-6) M) did not significantly increase baroreceptor sensitivity. The results of this study suggest that sinus sympathetic fibers produce a tonic sensitization of the baroreceptors.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effect of sympathetic sensitization of baroreceptors on XXXX .

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal nerve activity']

answer: @entity8 :: (MESH:D007674,Disease) :: ['renal nerve activity']


abstract: OBJECTIVES: This goal of this paper is to describe the reach, application, and effectiveness of an 8-week yoga therapy protocol with older @entity5 survivors within a Veterans Health Administration setting. METHODS: To document the reach of this intervention, recruitment efforts, attendance, and practice rates were tracked. To explore the application of the protocol to this population, physical therapy preassessment and observations by the yoga therapist were recorded to ascertain necessary pose modifications. Effectiveness was measured through pre- and post-course structured interviews, tracking self-reported symptoms of combat-related @entity1005 , @entity308 , @entity148 , @entity1295 , @entity22 , and @entity158 . RESULTS: Regarding reach, 15% of eligible veterans (n = 14) enrolled, participated in 3-16 classes (M  SD = 11.64  3.39), and practiced at home for 0-56 days (M  SD = 26.36  17.87). @entity1 were primarily Caucasian (n = 13), male (n = 13), ranged in age from 55 to 78 years (M  SD = 65.64  5.15), and had multiple medical problems. During application, substantial individualized modifications to the yoga therapy protocol were necessary. Effectiveness of the intervention was mixed. During post-course interviews, @entity1 reported a variety of qualitative benefits. Notably, the majority of @entity1 reported that breathing and relaxation techniques were the most useful to learn. Group comparisons of mean pre- and post-course scores on standardized measures showed no significant differences. CONCLUSIONS: A minority of older veterans express an interest in yoga, but those who do have high rates of class attendance and home practice. Careful physical pre-assessment and attentive therapists are required to undertake the adaptations required by @entity1 with multiple comorbidities. The effectiveness of yoga in this setting requires additional study.

title: Implementing yoga therapy adapted for older veterans who are XXXX survivors.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1005 :: ('MESH:D013313', 'Disease') :: ['posttraumatic stress disorder']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: BACKGROUND: Objective cost estimates and source of cost differences are needed across the spectrum of cognition, including cognitively normal (CN), @entity73 ( @entity73 ), newly discovered @entity303 , and prevalent @entity303 . METHODS: Subjects were a subset of the Mayo Clinic Study of Aging stratified-random sampling of Olmsted County, MN, residents aged 70 to 89  years. A neurologist reviewed provider-linked medical records to identify prevalent @entity303 (review date  =  index). Remaining subjects were invited to participate in prospective clinical/neuropsychological assessments; @entity1 were categorized as CN, @entity73 , or newly discovered @entity303 (assessment date  =  index). Costs for medical services/procedures 1-year pre-index (excluding indirect and long-term care costs) were estimated using line-item provider-linked administrative data. We estimated contributions of care-delivery site and comorbid conditions (including and excluding neuropsychiatric diagnoses) to between-category cost differences. RESULTS: Annual mean medical costs for CN, @entity73 , newly discovered @entity303 , and prevalent @entity303 were  6042,  6784,  9431,  11,678, respectively. Hospital inpatient costs contributed 70% of total costs for prevalent @entity303 and accounted for differences between CN and both prevalent and newly discovered @entity303 . Ambulatory costs accounted for differences between CN and @entity73 . Age-, sex-, education-adjusted differences reached significance for CN versus newly discovered and prevalent @entity303 and for @entity73 versus prevalent @entity303 . After considering all comorbid diagnoses, between-category differences were reduced (e.g., prevalent @entity303 minus @entity73 (from  4842 to  3575); newly discovered @entity303 minus CN (from  3578 to  711)). Following the exclusion of neuropsychiatric diagnoses from comorbidity adjustment, between-category differences tended to revert to greater differences. CONCLUSIONS: Cost estimates did not differ significantly between CN and @entity73 . Substantial differences between @entity73 and prevalent @entity303 reflected high inpatient costs for @entity303 and appear partly related to co-occurring @entity146 . Such comparisons can help inform models aimed at identifying where, when, and for which individuals proposed interventions might be cost-effective.

title: Direct medical costs and source of cost differences across the spectrum of XXXX : A population-based study.

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['MCI', 'mild cognitive impairment']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders']

answer: @entity73 :: (MESH:D003072,Disease) :: ['cognitive decline']


abstract: OBJECTIVE: To observe the curative effect of acupoint-injection and intramuscular-injection of Bacillus Calmette-Guerin (BCG) Polysaccharide Nucleic Acid for @entity565 . METHODS: Sixty @entity1 with @entity565 were equally randomized into acupoint-injection group and intramuscular-injection group. For @entity1 of the acupoint-injection group, 2 mL of BCG was injected into bilateral Feishu (BL 13, 1 mL for one side) once per day in the first 15 days, and once every other day in the rest 2.5 months except weekends. Intramuscular-injection was conducted at the lateral sites of the left or right buttock, 2 mL/time for each site, and the injection frequency was the same to that of the acupoint-injection. The therapeutic effect was assessed according to the standards of Guide Principles for Clinical Research of New Chinese Herbal Drugs (2002) and Asthma Group of Breathing Diseases of China Medical Association (2008). Changes of FEV 1 (forced expiratory volume in the first second)/FVC (forced vital capacity) and PEF% (peak expiratory flow) were detected using a pulmonary function detector. Serum IgA, IgM, IgG and IgE contents were assayed by using an autonomic biochemical analyzer. RESULTS: After 3 months' treatment, the scores of @entity1 ' symptoms and signs and serum IgE and IgG levels were significantly decreased in both muscular-injection and acupoint-injection groups (P<0.01), while asthma controlled test (ACT) scores FEV 1/FVC% and PEF% values were considerably increased in both groups compared to pre-treatment in the same one group (P<0.01). The effects of acupoint-injection were markedly superior to those of the intramuscular-injection in reducing clinical symptom-sign score, and serum IgE content, and in up-regulating ACT score, FEV 1/FVC% and PEF% levels (P<0.05, P<0.01). There were no significant differences in serum IgG, IgA and IgM levels between the two groups 3 months following the treatment (P>0.05). CONCLUSION: Acupoint-injection of BCG polysaccharide nucleic acid can effectively improve @entity565 @entity1 ' clinical symptoms and sings and pulmonary function, which may be closely associated with its function in down-regulating serum IgE and IgG levels.

title: [Comparison of therapeutic effects between acupoint-injection and intramuscular-injection of Bacillus Calmette-Guerin polysaccharide nucleic acid for XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity565 :: ('MESH:D001249', 'Disease') :: ['bronchial asthma']

answer: @entity565 :: (MESH:D001249,Disease) :: ['bronchial asthma']


abstract: OBJECTIVE: This study examines @entity1 factors to identify risks of 12-month mortality following periprosthetic @entity174 . Hospital charges were analyzed to quantify the financial burden for treatment modalities. METHODS: Data were retrospectively analyzed from a prospective database at a university hospital setting. One-hundred and thirteen @entity1 with a @entity3564 of the proximal or distal femur were identified. Risk factors for 12-month mortality were analyzed, and financial data were compared between the various treatment modalities. RESULTS: In all, 14% of @entity1 died (16 of 113) within 3 months and the 1-year mortality was 17.7% (20 of 113). @entity1 who died within 1 year had higher hospital charges (US 33 880    25 051 vs US 22 886    16 841; P = .01) and were older (87.6    8.5 vs 81.5    8.6; P = .004). Logistic regression analysis revealed age was the only significant predictor of 1-year mortality (P = .029, odds ratio 1.1). Analysis of financial data revealed 4 distinct groups (P < .05 between groups). Distal femoral revision arthroplasty (RA-DF) generated the highest hospital charges of US 91 035    25 579 (n = 3). The second most highly charged group included proximal @entity3330 treated with revision arthroplasty (US 34 078    17 832; n = 20) and hemi/total hip arthroplasty (THA; US 41 556    23 651; n = 8). The third most charged group underwent open reduction internal fixation of the proximal (US 18 706    6829; n = 35) and distal (US 22 381    10 835; n = 35) femur. Nonoperative treatment generated the lowest charges (US 6426    2899; n = 11). On average, the hospital lost money treating @entity1 with RA-DF (US -19 080    2022 per @entity1 ) and hemi/THA (US -6594    9305 per @entity1 ), while all other treatment groups were profitable. CONCLUSION: One-year mortality after periprosthetic @entity174 was 17.7%, is mostly influenced by age, and 80% of deaths occur within 3 months. @entity1 treated with primary/revision arthroplasty generate more hospital charges than internal fixation. The average @entity1 treated with revision arthroplasty of the distal femur or hemi/THA for a periprosthetic @entity174 resulted in net financial losses for the hospital.

title: Mortality and Financial Burden of XXXX of the Femur.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity3330 :: ('MESH:D005264', 'Disease') :: ['femoral fractures']

entities_list: @entity3564 :: ('MESH:D057068', 'Disease') :: ['periprosthetic fracture']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['femur fractures']

answer: @entity3564 :: (MESH:D057068,Disease) :: ['Periprosthetic Fractures']


abstract: The elderly (age 70+) @entity1 with orthopedic @entity130 is a rapidly growing subset of @entity1 in the United States. Due to increased medical comorbidities and decreased physiological reserve, morbidity and mortality after @entity130 may significantly differ from those @entity1 younger than 70 years old. A retrospective review was performed to investigate the effect of age on orthopedic @entity130 . A total of 870 records of @entity1 with orthopedic @entity130 from 2006 to 2009 at our Level One @entity130 center were reviewed. A database was created to include demographics, type and number of comorbid conditions at presentation, injuries, intensive care unit (ICU) and hospital length of stay, and description of the @entity174 . @entity1 aged 70 years and older had an increased number of comorbidities per @entity1 (3.3214-P < .0001). Length of stay in @entity1 aged 70 years and older was not significantly greater than that of the younger @entity1 . They spent an average of 14.76 days in the hospital compared to 13.42 days for the combined younger @entity1 (P = .45), but they spent significantly (P < .0001) more of their stay in the ICU (52.74% vs 34.9% for the younger cohorts). The number of @entity174 per @entity1 was lower (1.66) in the 70 and older age-group when compared to younger populations (P < .0001). The 70 and older group was more likely to have their injury due to a fall and less likely to have solid organ injuries. As the number of elderly @entity1 increase, continued research in the management of elderly @entity1 with @entity130 can lead to protocols and practice guidelines to improve outcomes.

title: Orthopedic XXXX and Aging: It Isn't Just About Mortality.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'person']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

answer: @entity130 :: (MESH:D014947,Disease) :: ['Trauma']


abstract: STUDY OBJECTIVES: Cognitive behavioral therapy for @entity22 (CBT-I) has been shown to improve both @entity308 , but predictors of @entity308 outcome following CBT-I have not been well examined. This study investigated how chronotype (i.e., morningness- eveningness trait) and changes in @entity25 ( @entity25 ) were related to changes in @entity308 among recipients of CBT-I. METHODS: Included were 419 adult @entity22 outpatients from a @entity25 clinic (43.20% males, age M  SD = 48.14  14.02). All @entity1 completed the Composite Scale of Morningness and attended a 6-session group CBT-I up to the second last session. @entity25 was extracted from sleep diary; @entity308 were assessed using the Beck Depression Inventory (BDI) prior to (Baseline), and at the end (End) of intervention. RESULTS: Multilevel structural equation modeling revealed that from Baseline to End, @entity25 increased and BDI decreased significantly. Controlling for age, sex, BDI, and @entity25 at Baseline, stronger evening chronotype and less improvement in @entity25 significantly and uniquely predicted less reduction in BDI from Baseline to End. Chronotype did not predict improvement in @entity25 . CONCLUSIONS: In an @entity22 outpatient sample, @entity25 and @entity308 improved significantly after a CBT-I group intervention. All chronotypes benefited from sleep improvement, but those with greater eveningness and/or less sleep improvement experienced less reduction in @entity308 symptom severity. This suggests that evening preference and @entity22 may have distinct relationships with mood, raising the possibility that the effect of CBT-I on @entity308 could be enhanced by assessing and addressing circadian factors.

title: Chronotype and Improved Sleep Efficiency Independently Predict Depressive Symptom Reduction after Group Cognitive Behavioral Therapy for XXXX .

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['sleep and depressive symptoms', 'depressive symptoms', 'depression', 'depressive']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disorders', 'sleep efficiency', 'SE']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia symptoms', 'insomnia']

answer: @entity22 :: (MESH:D007319,Disease) :: ['Insomnia']


abstract: @entity7980 were subjected to 12-15 min swimming exercise at 2/3 body lengths s-1 in a Blazka-type swim tunnel. @entity551 , cardiac output (ventral aortic blood flow) and heart rate were continuously recorded, and blood samples for measurement of arterial and mixed venous @entity26 tension were taken before and at the end of the exercise period. In a second group of fish, subjected to similar exercise regimes, blood samples were taken for analysis of the plasma concentrations of @entity2661 . @entity551 and cardiac output increase during exercise, while the mixed venous @entity26 tension decreases. The effect on cardiac output is due to an increase of both heart rate and @entity64 volume. There are no significant changes in either @entity1317 , or in the plasma concentrations of @entity2661 . Injection of the adrenergic neurone-blocking drug @entity17268 produces a @entity551 in resting cod, due to a decrease in the systemic vascular resistance. Exercising cod treated with @entity17268 have a significantly lower pre- and postbranchial blood pressure than exercising control cod. This is due mainly to a dramatic reduction in the systemic vascular resistance. The alpha-adrenoceptor antagonist @entity5521 does not further affect the blood pressure in cod treated with @entity17268 . It is concluded that the exercise @entity101 observed in cod depends on the effect of adrenergic vasomotor fibres maintaining the systemic vascular resistance, and also on the increase in cardiac output. An adrenergic innervation of the heart may play some role in the control of cardiac performance both at rest and during exercise, but the main cardioregulatory mechanism is likely to be non-adrenergic, most probably including cardiac control via variation of the cholinergic vagal cardioinhibitory tonus.

title: Blood pressure control during exercise in the XXXX , @entity7980 .

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity5521 :: ('MESH:D010646', 'Chemical') :: ['phentolamine']

entities_list: @entity7980 :: ('8049', 'Species') :: ['Atlantic cod']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['systemic or branchial vascular resistances']

entities_list: @entity2661 :: ('MESH:D002395', 'Chemical') :: ['catecholamines']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['decrease in postbranchial blood pressure', 'Pre- and postbranchial blood pressures']

entities_list: @entity17268 :: ('MESH:C045166', 'Chemical') :: ['bretylium']

answer: @entity7980 :: (8049,Species) :: ['Atlantic cod']


abstract: @entity7980 were subjected to 12-15 min swimming exercise at 2/3 body lengths s-1 in a Blazka-type swim tunnel. @entity551 , cardiac output (ventral aortic blood flow) and heart rate were continuously recorded, and blood samples for measurement of arterial and mixed venous @entity26 tension were taken before and at the end of the exercise period. In a second group of fish, subjected to similar exercise regimes, blood samples were taken for analysis of the plasma concentrations of @entity2661 . @entity551 and cardiac output increase during exercise, while the mixed venous @entity26 tension decreases. The effect on cardiac output is due to an increase of both heart rate and @entity64 volume. There are no significant changes in either @entity1317 , or in the plasma concentrations of @entity2661 . Injection of the adrenergic neurone-blocking drug @entity17268 produces a @entity551 in resting cod, due to a decrease in the systemic vascular resistance. Exercising cod treated with @entity17268 have a significantly lower pre- and postbranchial blood pressure than exercising control cod. This is due mainly to a dramatic reduction in the systemic vascular resistance. The alpha-adrenoceptor antagonist @entity5521 does not further affect the blood pressure in cod treated with @entity17268 . It is concluded that the exercise @entity101 observed in cod depends on the effect of adrenergic vasomotor fibres maintaining the systemic vascular resistance, and also on the increase in cardiac output. An adrenergic innervation of the heart may play some role in the control of cardiac performance both at rest and during exercise, but the main cardioregulatory mechanism is likely to be non-adrenergic, most probably including cardiac control via variation of the cholinergic vagal cardioinhibitory tonus.

title: Blood pressure control during exercise in the @entity7980 , XXXX .

answer: @entity7980 :: (8049,Species) :: ['Gadus morhua']


abstract: CONTEXT: Angelica sinensis (Oliv.) Diels (Apiaceae) polysaccharides ( @entity2574 ) may play a key role in anti- @entity63 activity. However, the anti- @entity731 activity and mechanism are unknown. OBJECTIVE: This study investigated the protective effects of @entity2574 against ox-LDL-induced senescence of EPCs and explored its underlying molecular mechanisms. MATERIALS AND METHODS: Mononuclear cells were isolated from bone marrow (BM) of SD @entity35 and differentiated to EPCs. EPCs were exposed to oxidized low-density lipoprotein (ox-LDL, 10     g/mL, 24   h) and incubated with or without high-dose (100     g/mL, 48   h) or low-dose (20     g/mL, 48   h) @entity2574 . Another group of EPCs was pre-treated with @entity2307 (100   nM, 45   min), a PI3K/ @entity2308 inhibitor. EPC senescence, telomerase activity, and @entity224 anion levels were assessed using SA-b-galactosidase staining, telomerase PCR-ELISA analysis, and DHE staining, respectively. The expression of related proteins, including @entity2308 , p- @entity2308 , @entity2215 , p- @entity2215 , and @entity8562 , were detected using western blot. RESULTS: EPCs (47.3%) were SA-b-gal positive after treatment by ox-LDL, additionally, ox-LDL significantly increased @entity224 anion levels (375% versus 100%), and inhibited telomerase activity (42% versus 100%). However, the pro-senescent effect of ox-LDL was attenuated about three-fold (16.7%), @entity224 anion levels were decreased more than two-fold (148%), and telomerase activity was recovered partly (88% versus 42%) in the EPCs when treated with @entity2574 (100     g/mL). The immunoblotting confirmed that @entity2574 attenuated inhibition of phosphorylation of @entity2308 and @entity2215 induced by ox-LDL and down-regulated increased the expression of gp91-phox. Moreover, some effects of @entity2574 were partially abrogated in the presence of @entity2307 . DISCUSSION: Ox-LDL induced senescence of EPCs via inhibition of telomerase activity, which was influenced by oxidative stress and the @entity2308 / @entity2215 pathway. The inhibition of EPC senescence by @entity2574 could be important for potential therapeutics. CONCLUSION: Treatment of EPCs with @entity2574 remarkably attenuates the harmful effects of ox-LDL via augmentation of @entity2308 / @entity2215 phosphorylation and inhibition of oxidative stress.

title: Angelica sinensis polysaccharides inhibit endothelial progenitor cell senescence through the reduction of oxidative stress and activation of the @entity2308 / XXXX pathway.

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity2307 :: ('MESH:C009687', 'Chemical') :: ['Wortmannin']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

answer: @entity2215 :: (7015,Gene) :: ['hTERT']


abstract: CONTEXT: Angelica sinensis (Oliv.) Diels (Apiaceae) polysaccharides ( @entity2574 ) may play a key role in anti- @entity63 activity. However, the anti- @entity731 activity and mechanism are unknown. OBJECTIVE: This study investigated the protective effects of @entity2574 against ox-LDL-induced senescence of EPCs and explored its underlying molecular mechanisms. MATERIALS AND METHODS: Mononuclear cells were isolated from bone marrow (BM) of SD @entity35 and differentiated to EPCs. EPCs were exposed to oxidized low-density lipoprotein (ox-LDL, 10     g/mL, 24   h) and incubated with or without high-dose (100     g/mL, 48   h) or low-dose (20     g/mL, 48   h) @entity2574 . Another group of EPCs was pre-treated with @entity2307 (100   nM, 45   min), a PI3K/ @entity2308 inhibitor. EPC senescence, telomerase activity, and @entity224 anion levels were assessed using SA-b-galactosidase staining, telomerase PCR-ELISA analysis, and DHE staining, respectively. The expression of related proteins, including @entity2308 , p- @entity2308 , @entity2215 , p- @entity2215 , and @entity8562 , were detected using western blot. RESULTS: EPCs (47.3%) were SA-b-gal positive after treatment by ox-LDL, additionally, ox-LDL significantly increased @entity224 anion levels (375% versus 100%), and inhibited telomerase activity (42% versus 100%). However, the pro-senescent effect of ox-LDL was attenuated about three-fold (16.7%), @entity224 anion levels were decreased more than two-fold (148%), and telomerase activity was recovered partly (88% versus 42%) in the EPCs when treated with @entity2574 (100     g/mL). The immunoblotting confirmed that @entity2574 attenuated inhibition of phosphorylation of @entity2308 and @entity2215 induced by ox-LDL and down-regulated increased the expression of gp91-phox. Moreover, some effects of @entity2574 were partially abrogated in the presence of @entity2307 . DISCUSSION: Ox-LDL induced senescence of EPCs via inhibition of telomerase activity, which was influenced by oxidative stress and the @entity2308 / @entity2215 pathway. The inhibition of EPC senescence by @entity2574 could be important for potential therapeutics. CONCLUSION: Treatment of EPCs with @entity2574 remarkably attenuates the harmful effects of ox-LDL via augmentation of @entity2308 / @entity2215 phosphorylation and inhibition of oxidative stress.

title: Angelica sinensis polysaccharides inhibit endothelial progenitor cell senescence through the reduction of oxidative stress and activation of the XXXX / @entity2215 pathway.

answer: @entity2308 :: (24185(Tax:10116),Gene) :: ['Akt']


abstract: Twenty-six @entity1 with @entity0 were treated with intensive @entity632 (Adria Laboratories, Columbus, @entity2145 ) as a single agent administered for three successive days once a month. Dosing started at 25 or 30 mg/m2/d three times, and was escalated by 5 mg/m2/d monthly to maximal tolerance based on hematologic, mucosal, or cardiac @entity137 . Four @entity1 (15%) had complete remissions (CRs) pathologically proven, and six others (23%) sustained complete CRs, but were found to have microscopic @entity41 (three) or refused biopsy (three). Twelve @entity1 (46%) attained partial remission (PR). The overall response (85%) and CR rates (38%) were approximately double those reported with conventional @entity632 doses. Median unmaintained remission duration for the ten @entity1 in CR was 11 months. @entity1370 , determined by radionuclide physiologic studies, occurred in 16 @entity1 at a mean dose of 459 mg/m2; three @entity1 developed reversible congestive failure. There were no toxic deaths. The median overall survival was 18 months. These data suggest that there is steep dose responsiveness to @entity632 in @entity0 , and that more effective techniques for using @entity632 may exist than those conventionally used.

title: A phase I-II study of intensive-dose XXXX for advanced @entity0 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['Adriamycin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['metastatic breast cancer']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor']

entities_list: @entity1370 :: ('MESH:D066126', 'Disease') :: ['Cardiotoxicity']

answer: @entity632 :: (MESH:D004317,Chemical) :: ['adriamycin']


abstract: Twenty-six @entity1 with @entity0 were treated with intensive @entity632 (Adria Laboratories, Columbus, @entity2145 ) as a single agent administered for three successive days once a month. Dosing started at 25 or 30 mg/m2/d three times, and was escalated by 5 mg/m2/d monthly to maximal tolerance based on hematologic, mucosal, or cardiac @entity137 . Four @entity1 (15%) had complete remissions (CRs) pathologically proven, and six others (23%) sustained complete CRs, but were found to have microscopic @entity41 (three) or refused biopsy (three). Twelve @entity1 (46%) attained partial remission (PR). The overall response (85%) and CR rates (38%) were approximately double those reported with conventional @entity632 doses. Median unmaintained remission duration for the ten @entity1 in CR was 11 months. @entity1370 , determined by radionuclide physiologic studies, occurred in 16 @entity1 at a mean dose of 459 mg/m2; three @entity1 developed reversible congestive failure. There were no toxic deaths. The median overall survival was 18 months. These data suggest that there is steep dose responsiveness to @entity632 in @entity0 , and that more effective techniques for using @entity632 may exist than those conventionally used.

title: A phase I-II study of intensive-dose @entity632 for advanced XXXX .

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: PURPOSE: The purpose was to describe the medial rectus muscle elongation (MRE) procedure to treat very large-angle @entity5971 ( @entity5971 ) with surgery on a lower number of muscles. METHODS: Twenty @entity1 with very large-angle @entity5971 (more than 70 @entity1726 ) underwent the MRE procedure. In the MRE procedure, the muscle was split longitudinally into three parts. The wider central part was sutured with 6/0 vicryl and disinserted. The distal end of the peripheral parts (still attached to the original insertion), 7-9  mm away from the insertion, was sutured to the proximal end of the central part. At the end of the procedure, the distance of the @entity254 site from the insertion was named as the final elongation. The dose-response effect of the final elongation was calculated in bilateral MRE cases. The mean of the dose-response effect, obtained in the binocular surgery group, was used in the monocular surgery group to calculate the resection effect of lateral rectus (LR) muscle. RESULTS: Eleven @entity1 underwent bilateral MRE and nine @entity1 underwent unilateral MRE and LR muscle resection. The mean preoperative far and near deviation was 94.10        19.33 @entity1726 . The mean postoperative deviation was 14.60        18.07 @entity1726 for far and 14.50        18.23 @entity1726 for near deviation. In bilateral MRE cases, the mean dose-response effect of the elongation was 5.53        0.67 @entity1726 /mm for far and 5.58        0.69 @entity1726 /mm for near deviation. The mean LR muscle resection effect was 6.41        1.99 @entity1726 /mm for far and 6.28        1.93 @entity1726 /mm for near deviation. CONCLUSION: The MRE procedure seems an acceptable method to treat very large-angle @entity5971 with surgery on a lower number of muscles.

title: Medial rectus muscle elongation, a technique to treat very large-angle XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

answer: @entity5971 :: (MESH:D004948,Disease) :: ['esotropia']


abstract: UNASSIGNED: Coping with cold winter conditions is a major challenge for many insects. In early spring we observed newly emerged @entity238 subobscura, which had overwintered as larvae and pupae. As temperatures increase during spring these flies are faced with higher minimum and maximum temperatures in their natural microhabitat. Thus, there is a potential costly mismatch between winter and early spring acclimatization and the increased ambient temperatures later in adult life. We obtained individuals from a natural Danish population of D. subobscura and acclimated them in the laboratory to 20  C for one generation, and compared critical thermal maximum (CTmax) and minimum (CTmin) to that of individuals collected directly from their natural microhabitat. The two populations (laboratory and field) were subsequently both held in the laboratory at 20  C and tested for their CTmax and CTmin every third day for 28days. At the first day of testing, field acclimatized D. subobscura had both higher heat and cold resistance compared to laboratory flies, and thereby a considerable larger thermal scope. Following transfer to the laboratory, cold and heat resistance of the field flies decreased over time relative to the laboratory flies. Despite the substantial decrease in thermal tolerances the thermal scope remained larger for field acclimatized individuals for the duration of the experiment. We conclude that flies acclimatized to their natural microhabitat had increased cold resistance, without a loss in @entity6167 . Thus while a negative correlation between cold and @entity6167 is typically observed in laboratory studies in @entity238 sp., this was not observed for field acclimatized D. subobscura in this study. We suggest that this is an adaptation to juvenile overwintering in temperate cold environments, where developmental (winter) temperatures can be much lower than temperatures experienced by reproducing adults after emergence (spring). The ability to gain cold tolerance through acclimatization without a parallel loss of @entity6167 affects thermal scope and suggests that high and low thermal tolerance act through mechanisms with different dynamics and reversibility.

title: No trade-off between high and low temperature tolerance in a winter acclimatized Danish XXXX subobscura population.

entities_list: @entity6167 :: ('MESH:D018883', 'Disease') :: ['heat tolerance']

entities_list: @entity238 :: ('7227', 'Species') :: ['Drosophila']

answer: @entity238 :: (7227,Species) :: ['Drosophila']


abstract: UNASSIGNED: Therapy for @entity30 (CD) with @entity10227 is limited by systemic side effects. A novel formulation of fixed-dose, delayed-release @entity4446 (DR-6MP) was developed, with local effect on the gut immune system and minimal absorption. The aim of this study was to evaluate the safety and efficacy of DR- @entity7275 in @entity1 with moderately severe CD compared to systemically delivered @entity4446 ( @entity4446 ). Seventy CD @entity1 were enrolled into a 12-week, double-blind controlled trial. The primary end-point was the percentage of subjects with clinical remission [Crohn's Disease Activity Index (CDAI)  <  150] or clinical response (100-point CDAI reduction). Twenty-six (56  5%) and 13 (54  2%) subjects from the DR- @entity7275 and @entity4446 cohorts, respectively, completed the study. DR- @entity7275 had similar efficacy to @entity4446 following 12 weeks of treatment. However, the time to maximal clinical response was 8 weeks for DR- @entity7275 versus 12 weeks for @entity4446 . A higher proportion of @entity1 on DR- @entity7275 showed clinical remission at week 8. A greater improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) score was noted in the DR- @entity7275 group. DR- @entity7275 led to a decrease of @entity8729 (+) expression on T cells, implying a reduction of lymphocyte adhesion to site of inflammation. DR- @entity7275 was safer than @entity4446 , with significantly fewer adverse events (AEs). There was no evidence of drug-induced leucopenia in the DR- @entity7275 group; the proportion of subjects who developed hepatotoxicity was lower for the DR- @entity7275 . Non-absorbable DR- @entity7275 is safe and biologically active in the gut. It is clinically effective, exerting a systemic immune response with low systemic bioavailability and a low incidence of side effects.

title: Oral administration of non-absorbable delayed release @entity4446 is locally active in the gut, exerts a systemic immune effect and alleviates XXXX with low rate of side effects: results of double blind Phase II clinical trial.

entities_list: @entity4446 :: ('MESH:D015122', 'Chemical') :: ['Purinethol', '6-mercaptopurine']

entities_list: @entity10227 :: ('CHEBI:35666', 'Chemical') :: ['thiopurines']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

answer: @entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']


abstract: UNASSIGNED: Therapy for @entity30 (CD) with @entity10227 is limited by systemic side effects. A novel formulation of fixed-dose, delayed-release @entity4446 (DR-6MP) was developed, with local effect on the gut immune system and minimal absorption. The aim of this study was to evaluate the safety and efficacy of DR- @entity7275 in @entity1 with moderately severe CD compared to systemically delivered @entity4446 ( @entity4446 ). Seventy CD @entity1 were enrolled into a 12-week, double-blind controlled trial. The primary end-point was the percentage of subjects with clinical remission [Crohn's Disease Activity Index (CDAI)  <  150] or clinical response (100-point CDAI reduction). Twenty-six (56  5%) and 13 (54  2%) subjects from the DR- @entity7275 and @entity4446 cohorts, respectively, completed the study. DR- @entity7275 had similar efficacy to @entity4446 following 12 weeks of treatment. However, the time to maximal clinical response was 8 weeks for DR- @entity7275 versus 12 weeks for @entity4446 . A higher proportion of @entity1 on DR- @entity7275 showed clinical remission at week 8. A greater improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) score was noted in the DR- @entity7275 group. DR- @entity7275 led to a decrease of @entity8729 (+) expression on T cells, implying a reduction of lymphocyte adhesion to site of inflammation. DR- @entity7275 was safer than @entity4446 , with significantly fewer adverse events (AEs). There was no evidence of drug-induced leucopenia in the DR- @entity7275 group; the proportion of subjects who developed hepatotoxicity was lower for the DR- @entity7275 . Non-absorbable DR- @entity7275 is safe and biologically active in the gut. It is clinically effective, exerting a systemic immune response with low systemic bioavailability and a low incidence of side effects.

title: Oral administration of non-absorbable delayed release XXXX is locally active in the gut, exerts a systemic immune effect and alleviates @entity30 with low rate of side effects: results of double blind Phase II clinical trial.

answer: @entity4446 :: (MESH:D015122,Chemical) :: ['6-mercaptopurine']


abstract: OBJECTIVE: To describe 2 cases of @entity5506 ( @entity5506 ) following the administration of @entity1156 -adjuvanted @entity683 vaccine. CASE SUMMARY: An 83-year-old white @entity1 developed persistent @entity590 , @entity4841 , and @entity6250 about 2 days after receiving @entity683 vaccine. Clinical signs and laboratory evaluations suggested @entity5506 . The @entity1 was treated with high-dose corticosteroids and immunoglobulins, and her clinical condition improved. A 74-year-old white @entity1 developed severe @entity490 and @entity1395 3 days after the administration of @entity683 vaccine. Clinical signs and laboratory evaluations disclosed @entity5506 . She was treated with @entity288 , rehydration, and blood transfusion; however, she died about 48 hours after hospitalization. DISCUSSION: @entity5506 has been rarely described following @entity683 vaccine administration. In the cases described here, the causal relationship between @entity683 vaccination and the occurrence of @entity5506 , assessed by means of World Health Organization criteria, was scored as probable. It has been proposed that the mechanism whereby vaccines induce @entity792 can be molecular mimicry, although a possible role of other vaccine constituents, with particular regard for adjuvants, such as @entity1156 , can not be excluded. @entity24288 , a constituent of @entity1156 , has been suggested as a causative agent of autoimmune reactions. However, it is not clear how and under what conditions squalene can cause immune responses. CONCLUSIONS: Influenza vaccination may rarely trigger severe @entity5506 , shortly after vaccine administration. A mechanism of molecular mimicry is probably involved in the development of these reactions, although the possible role of adjuvants can not be excluded. @entity1 should be instructed to report signs and symptoms of @entity792 occurring in the first weeks after administration of @entity683 vaccine.

title: Autoimmune hemolytic anemia following XXXX -adjuvanted @entity683 vaccine administration: a report of two cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'woman', 'patient']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']

entities_list: @entity5506 :: ('MESH:D000744', 'Disease') :: ['autoimmune hemolytic anemia', 'AIHA']

entities_list: @entity6250 :: ('MESH:D038061', 'Disease') :: ['lower limb hypostenia']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune responses', 'autoimmune disorders']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity4841 :: ('MESH:D018771', 'Disease') :: ['polyarthralgia']

entities_list: @entity590 :: ('MESH:D008305', 'Disease') :: ['hyperpyrexia']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity1156 :: (MESH:C089950,Chemical) :: ['MF59']


abstract: OBJECTIVE: To describe 2 cases of @entity5506 ( @entity5506 ) following the administration of @entity1156 -adjuvanted @entity683 vaccine. CASE SUMMARY: An 83-year-old white @entity1 developed persistent @entity590 , @entity4841 , and @entity6250 about 2 days after receiving @entity683 vaccine. Clinical signs and laboratory evaluations suggested @entity5506 . The @entity1 was treated with high-dose corticosteroids and immunoglobulins, and her clinical condition improved. A 74-year-old white @entity1 developed severe @entity490 and @entity1395 3 days after the administration of @entity683 vaccine. Clinical signs and laboratory evaluations disclosed @entity5506 . She was treated with @entity288 , rehydration, and blood transfusion; however, she died about 48 hours after hospitalization. DISCUSSION: @entity5506 has been rarely described following @entity683 vaccine administration. In the cases described here, the causal relationship between @entity683 vaccination and the occurrence of @entity5506 , assessed by means of World Health Organization criteria, was scored as probable. It has been proposed that the mechanism whereby vaccines induce @entity792 can be molecular mimicry, although a possible role of other vaccine constituents, with particular regard for adjuvants, such as @entity1156 , can not be excluded. @entity24288 , a constituent of @entity1156 , has been suggested as a causative agent of autoimmune reactions. However, it is not clear how and under what conditions squalene can cause immune responses. CONCLUSIONS: Influenza vaccination may rarely trigger severe @entity5506 , shortly after vaccine administration. A mechanism of molecular mimicry is probably involved in the development of these reactions, although the possible role of adjuvants can not be excluded. @entity1 should be instructed to report signs and symptoms of @entity792 occurring in the first weeks after administration of @entity683 vaccine.

title: Autoimmune hemolytic anemia following @entity1156 -adjuvanted XXXX vaccine administration: a report of two cases.

answer: @entity683 :: (MESH:D007251,Disease) :: ['influenza']


abstract: Whole oilseeds such as soya beans have been utilized in dairy rations to supply additional fat and protein. However, antinutritional components contained in soya beans, such as trypsin inhibitors and haemagglutinins (lectins) may alter digestibility of nutrients and consequently affect animal performance. The objective of the present experiment was to quantify the effect of different levels of whole raw soya beans in diets of dairy @entity291 on nutrient intake, total tract digestion, nutrient balances and milk yield and composition. Sixteen mid to late-lactation @entity291 (228    20 days in milk; mean    SD) were used in four replicated 4 * 4 Latin square design experiment with 21-d periods. @entity291 were assigned to each square according to milk yield and DIM. The animals were randomly allocated to treatments: control (without soya beans addition; CO), WS9, WS18 and WS27, with addition of 9%, 18% and 27% of whole raw soya bean in diet on a @entity62 ( @entity62 ) basis respectively. All diets contained identical forage and concentrate components and consisted of @entity2829 silage and concentrate based on ground @entity4336 and soya beans at a ratio of 60:40. There were no differences in OM, CP, NDF and NEL intakes (kg/day and MJ/day) among the treatments (p > 0.05). However, @entity62 and NFC intakes were negatively affected (p = 0.04 and p < 0.01, respectively) and ether extract (EE) intake was positively affected (p < 0.01). Total tract digestion increased linearly with whole raw soya beans for EE (p < 0.01) and NDF (p = 0.01). The excretion (kg/day) of digested soya beans grains increased linearly according to addition of whole raw soya beans. However, the nutritive characteristics of excreted grains were not altered. Milk (kg), milk @entity1132 (kg) and protein (kg) yield decreased linearly (p < 0.01, p < 0.01 and p = 0.04, respectively) milk fat content (%) increased linearly (p < 0.01) with whole raw soya beans inclusion. Increasing addition of whole raw soya beans affected milk @entity844 profile with a linear decrease of cis-9-trans 11CLA and total saturated FA; and linear increase of total unsaturated and @entity7608 FA. Energy balance was positively affected (p = 0.03) by whole raw soya beans as well as efficiency of NEL milk/DE intake (p = 0.02). @entity1568 balance and microbial protein synthesis were not affected by whole raw soya beans. Increasing doses of whole raw soya beans decreased @entity62 intake and milk yield, however, led to an increase of unsaturated acids in milk and higher milk fat concentration.

title: Total tract nutrient digestion and milk XXXX profile of dairy @entity291 fed diets containing different levels of whole raw soya beans.

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['Nitrogen']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['DM', 'dry matter']

answer: @entity844 :: (CHEBI:35366,Chemical) :: ['fatty acid']


abstract: Whole oilseeds such as soya beans have been utilized in dairy rations to supply additional fat and protein. However, antinutritional components contained in soya beans, such as trypsin inhibitors and haemagglutinins (lectins) may alter digestibility of nutrients and consequently affect animal performance. The objective of the present experiment was to quantify the effect of different levels of whole raw soya beans in diets of dairy @entity291 on nutrient intake, total tract digestion, nutrient balances and milk yield and composition. Sixteen mid to late-lactation @entity291 (228    20 days in milk; mean    SD) were used in four replicated 4 * 4 Latin square design experiment with 21-d periods. @entity291 were assigned to each square according to milk yield and DIM. The animals were randomly allocated to treatments: control (without soya beans addition; CO), WS9, WS18 and WS27, with addition of 9%, 18% and 27% of whole raw soya bean in diet on a @entity62 ( @entity62 ) basis respectively. All diets contained identical forage and concentrate components and consisted of @entity2829 silage and concentrate based on ground @entity4336 and soya beans at a ratio of 60:40. There were no differences in OM, CP, NDF and NEL intakes (kg/day and MJ/day) among the treatments (p > 0.05). However, @entity62 and NFC intakes were negatively affected (p = 0.04 and p < 0.01, respectively) and ether extract (EE) intake was positively affected (p < 0.01). Total tract digestion increased linearly with whole raw soya beans for EE (p < 0.01) and NDF (p = 0.01). The excretion (kg/day) of digested soya beans grains increased linearly according to addition of whole raw soya beans. However, the nutritive characteristics of excreted grains were not altered. Milk (kg), milk @entity1132 (kg) and protein (kg) yield decreased linearly (p < 0.01, p < 0.01 and p = 0.04, respectively) milk fat content (%) increased linearly (p < 0.01) with whole raw soya beans inclusion. Increasing addition of whole raw soya beans affected milk @entity844 profile with a linear decrease of cis-9-trans 11CLA and total saturated FA; and linear increase of total unsaturated and @entity7608 FA. Energy balance was positively affected (p = 0.03) by whole raw soya beans as well as efficiency of NEL milk/DE intake (p = 0.02). @entity1568 balance and microbial protein synthesis were not affected by whole raw soya beans. Increasing doses of whole raw soya beans decreased @entity62 intake and milk yield, however, led to an increase of unsaturated acids in milk and higher milk fat concentration.

title: Total tract nutrient digestion and milk @entity844 profile of dairy XXXX fed diets containing different levels of whole raw soya beans.

answer: @entity291 :: (9913,Species) :: ['cows']


abstract: UNASSIGNED: @entity4243 ( @entity4243 ) is a heritable disorder of connective tissue caused by pathological variants in the @entity1414 gene, which encodes the a1 chain of type III collagen. Type III collagen is a major component of skin, arterial walls, and the gastrointestinal tract. @entity1413 manifests as an increased risk of @entity397 , perforation, and dissection of these structures. The most disruptive gene variants affect the collagen helix via glycine substitutions or splice donor site mutations. The C-propeptide region of @entity1414 includes exons 49-52 and has a crucial role in initiating the C-terminal assembly of procollagen monomers in the early stages of collagen biosynthesis. Nineteen @entity1414 variants have previously been reported in these exons, of which four were associated with a severe @entity4243 phenotype. We identified two novel C-propeptide missense variants; @entity72140 , @entity72141 , and a non-stop mutation, @entity72142 , p. (*1467Leuext*45). These variants produce variable phenotypes ranging from obvious acrogeria to classical or hypermobile @entity15354 . A previously reported variant @entity72143 is of unknown clinical significance but likely benign, based on this study. Assigning disease pathogenicity remains complex, clinical phenotyping and crystal structure evidence being crucial. We briefly compare reported phenotypes for @entity1 with missense variants in the C-propeptide domain for other @entity1 collagen disorders including @entity13239 and @entity4173 ( @entity6926 ).    2015 Wiley Periodicals, Inc.

title: Clinical, structural, biochemical and X-ray crystallographic correlates of pathogenicity for variants in the C-propeptide region of the XXXX gene.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity72140 :: ('p|SUB|P|1440|L', 'ProteinMutation') :: ['p.Pro1440Leu']

entities_list: @entity72141 :: ('p|SUB|R|1432|L', 'ProteinMutation') :: ['p.Arg1432Leu']

entities_list: @entity4243 :: ('MESH:D004535', 'Disease') :: ['vEDS', 'Vascular Ehlers-Danlos syndrome']

entities_list: @entity6926 :: ('MESH:D010013', 'Disease') :: ['osteogenesis imperfecta']

entities_list: @entity1413 :: ('MESH:D003095', 'Disease') :: ['Collagen III protein deficiency']

entities_list: @entity72143 :: ('p|SUB|K|1313|R', 'ProteinMutation') :: ['p.Lys1313Arg']

answer: @entity1414 :: (1281,Gene) :: ['COL3A1']


abstract: INTRODUCTION: @entity16 ( @entity16 ) are a major cause of @entity1353 , orthopnea, and @entity1576 . The aim of the study was to obtain diagnostic findings, assess therapeutic options, and review outcomes in @entity6841 @entity1 . METHODS: From 2004 to 2013, @entity1 with @entity6841 referred to the author's institution were studied using clinical, pulmonary function, and electrodiagnostic tests. A PubMed search of published @entity6841 reports was also done. @entity6841 ( @entity6841 ) and @entity6841 ( @entity6841 ) @entity1 were compared. RESULTS: The analysis consisted of 10 @entity6841 and 9 @entity6841 @entity1 seen by the author, plus previous reports of 18 @entity6841 and 40 @entity6841 @entity1 . @entity6841 @entity1 were older (in the author's series) and were more often @entity101 . They reported @entity158 less often, @entity1353 and orthopnea more often, and had worse results on pulmonary function tests than @entity6841 @entity1 . CONCLUSIONS: @entity6841 and @entity6841 are probably 2 variants of the same, immune-mediated focal @entity16 . Electrodiagnosis is a valuable confirmatory test for @entity6841 . Muscle Nerve, 2015.

title: XXXX : A case series and review of the literature.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity6841 :: ('MESH:C565820', 'Disease') :: ['bilateral PN', 'UPN', 'Unilateral PN', 'BPN', 'PN']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy', 'PNs', 'Phrenic neuropathies']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['hypercapnic respiratory failure']

answer: @entity16 :: (MESH:D009422,Disease) :: ['Idiopathic phrenic neuropathies']


abstract: PURPOSE: The @entity1030 assessment test (CAT) is a questionnaire that assesses the impact of @entity1030 ( @entity1030 ) on health status, but some @entity1 have difficulties filling it up by themselves. We examined whether the mode of administration of the Spanish version of CAT (self vs. interviewer) influences its scores and/or psychometric properties. METHODS: Observational, prospective study in 49 Spanish centers that includes clinically stable @entity1030 @entity1 (n  =  153) and @entity1 hospitalized because of an exacerbation (ECOPD; n  =  224). The CAT was self-administered (CAT-SA) or administered by an interviewer (CAT-IA) based on the investigator judgment of the @entity1 's capacity. To assess convergent validity, the Saint George's @entity1576 Questionnaire (SGRQ) and the London Chest Activity of Daily Living (LCADL) instrument were also administered. Psychometric properties were compared across modes of administration. RESULTS: A total of 118 @entity1 (31  %) completed the CAT-SA and 259 (69  %) CAT-IA. Multiple regression analysis showed that mode of administration did not affect CAT scores. The CAT showed excellent psychometric properties in both modes of administration. Internal consistency coefficients (Cronbach's alpha) were high (0.86 for CAT-SA and 0.85 for CAT-IA) as was test-retest reliability (intraclass correlation coefficients of 0.83 for CAT-SA and CAT-IA). Correlations with SGRQ and LCADL were moderate to strong both in CAT-SA and CAT-IA, indicating good convergent validity. Similar results were observed when testing longitudinal validity. CONCLUSIONS: The mode of administration does not influence CAT scores or its psychometric properties. Hence, both modes of administration can be used in clinical practice depending on the physician judgment of @entity1 's capacity.

title: Does the XXXX assessment test (CAT(TM)) questionnaire produce similar results when self- or interviewer administered?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['Respiratory Disease']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD']

answer: @entity1030 :: (MESH:D029424,Disease) :: ['COPD']


abstract: BACKGROUND: The majority of @entity1 with @entity43 (EOC) relapse after initially responding to @entity902 -based chemotherapy, and develop resistance. The genomic features involved in drug resistance are unknown. To unravel some of these features, we investigated the mutational profile of genes involved in pathways related to drug sensitivity in a cohort of matched @entity5 obtained at first surgery (Ft-S) and second surgery (Sd-S). @entity1 AND METHODS: Matched biopsies (33) taken at Ft-S and Sd-S were selected from the 'Pandora' @entity5 tissue collection. DNA libraries for 65 genes were generated using the TruSeq Custom Amplicon kit and sequenced on MiSeq (Illumina). Data were analyzed using a high-performance cluster computing platform (Cloud4CARE project) and independently validated. RESULTS: A total of 2270 somatic mutations were identified (89.85% base substitutions 8.19% indels, and 1.92% unknown). Homologous recombination (HR) genes and @entity876 were mutated in the majority of Ft-S, while ATM, ATR, @entity14583 and @entity5255 were mutated in the entire dataset. Only 2% of mutations were conserved between matched Ft-S and Sd-S. Mutations detected at second surgery clustered @entity1 in two groups characterized by different mutational profiles in genes associated with HR, @entity10412 , miRNA biogenesis and signal transduction. CONCLUSIONS: There was a low level of concordance between Ft-S and Sd-S in terms of mutations in genes involved in key processes of @entity5 growth and drug resistance. This result suggests the importance of future longitudinal analyses to improve the clinical management of relapsed EOC.

title: Profiling XXXX gene mutations in @entity43 biopsies by targeted next-generation sequencing: a retrospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['stage III-IV epithelial ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']